|
05 Sep 2019 |
European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union
|
|
05 Sep 2019 |
Biotest Achieves Important Clinical Milestone for IgG Next Generation
|
|
04 Sep 2019 |
Zydus to launch novel biologic for rabies, TwinrabTM
|
|
04 Sep 2019 |
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa
|
|
30 Aug 2019 |
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
|
|
29 Aug 2019 |
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
|
|
29 Aug 2019 |
European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
|
|
29 Aug 2019 |
Anifrolumab Phase III trial meets primary endpoint in systemic lupus erythematosus
|
|
28 Aug 2019 |
Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder
|
|
28 Aug 2019 |
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
|
28 Aug 2019 |
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
27 Aug 2019 |
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
|
|
23 Aug 2019 |
GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma
|
|
22 Aug 2019 |
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
|
|
21 Aug 2019 |
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
|
|
21 Aug 2019 |
ChemomAb Ltd., Announces Data from Phase 1 Study of CM-101 Subcutaneous Formulation Demonstrating Comparable Exposure to The Intravenous CM-101 Formulation
|
|
21 Aug 2019 |
Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer
|
|
20 Aug 2019 |
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
|
|
14 Aug 2019 |
ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204
|
|
14 Aug 2019 |
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
|
|
14 Aug 2019 |
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)
|
|
13 Aug 2019 |
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
|
|
13 Aug 2019 |
Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial
|
|
12 Aug 2019 |
Ridgeback Biotherapeutics LP announces an update on mAb114, an experimental treatment for Ebola
|
|
12 Aug 2019 |
PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths
|
